Sarpogrelate HCl, a selective 5-HT2A antagonist, retards the progression of atherosclerosis through a novel mechanism

Area of Science:

• Cardiovascular Research
• Pharmacology
• Atherosclerosis Studies

Background:

• Sarpogrelate HCl is clinically utilized for preventing arterial thrombosis.
• The impact of sarpogrelate HCl on the development of atherosclerosis remains largely uncharacterized.
• Investigating novel therapeutic targets for atherosclerosis is crucial.

Purpose of the Study:

• To evaluate the efficacy of sarpogrelate HCl in mitigating atherosclerosis progression.
• To explore the synergistic effects of sarpogrelate HCl and vitamin E on atherosclerosis.
• To elucidate the underlying mechanisms of sarpogrelate HCl's action on atherosclerotic lesions.

Main Methods:

• A rabbit model of atherosclerosis was established using a 0.5% cholesterol diet.
• Rabbits were administered vitamin E and/or sarpogrelate HCl for 8 weeks.
• Key markers of atherosclerosis, vascular function, and molecular pathways were analyzed.

Main Results:

• Sarpogrelate HCl significantly reduced atherosclerotic lesion area, an effect amplified by vitamin E.
• The drug increased nitric oxide (NO) release and tended to improve acetylcholine-induced vasodilation.
• Upregulation of endothelial nitric oxide synthase (eNOS) mRNA and reduced superoxide anion release were observed.

Conclusions:

• Sarpogrelate HCl demonstrates a protective effect against atherosclerosis progression in rabbits.
• Concomitant administration with vitamin E enhances the anti-atherosclerotic effects of sarpogrelate HCl.
• Mechanisms may involve eNOS upregulation and antiproliferative actions on vascular cells.